ConductScience.org, home

Paper20046573

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Ramakrishnan MS and 6 others. MAbs, 2009. Cited by 198 papers, by iCite.

Cite this record

ConductScience Library. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Papers, record 20046573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20046573

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.
PubMed
Journal
MAbs
PubMed
Year
2009
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
198
iCite
Relative citation ratio, by iCite
4.45
iCite
Revised in PubMed
2026-01-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ramakrishnan MSMelarkode S
2Eswaraiah AAnand
3Crombet TTania
4Piedra PPatricia
5Saurez GGiselle
6Iyer HHarish
7Arvind ASA S

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic AgentsMajor topic
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
GliomaMajor topic
Head and Neck NeoplasmsMajor topic
Nasopharyngeal NeoplasmsMajor topic
Adolescent
Adult
Aged
Animals
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase II as Topic
Cuba
Humans
India
Middle Aged

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04223024Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal CarcinomaBackgroundClinicalTrials.gov
NCT04456322Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal CarcinomaBackgroundClinicalTrials.gov

Download CSV of trials

References17

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117367263Incidence and management of cutaneous toxicities associated with cetuximab.Expert Opin Drug Saf2007https://conductscience.org/library/papers/17367263PubMed
217827980Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.Cancer Biol Ther2007https://conductscience.org/library/papers/17827980PubMed
314701780Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.J Clin Oncol2004https://conductscience.org/library/papers/14701780PubMed
418337605EGFR antagonists in cancer treatment.N Engl J Med2008https://conductscience.org/library/papers/18337605PubMed
515117987Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.J Clin Oncol2004https://conductscience.org/library/papers/15117987PubMed
616249358Nimotuzumab: evidence of clinical benefit without rash.Oncologist2005https://conductscience.org/library/papers/16249358PubMed
715950538Recent developments related to the EGFR as a target for cancer chemotherapy.Curr Opin Pharmacol2005https://conductscience.org/library/papers/15950538PubMed
817010747Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.J Am Acad Dermatol2006https://conductscience.org/library/papers/17010747PubMed
912237899Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody.Int J Cancer2002https://conductscience.org/library/papers/12237899PubMed
1017159497Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.Anticancer Drugs2007https://conductscience.org/library/papers/17159497PubMed
1116467544Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med2006https://conductscience.org/library/papers/16467544PubMed
1215864276ERBB receptors and cancer: the complexity of targeted inhibitors.Nat Rev Cancer2005https://conductscience.org/library/papers/15864276PubMed
1315059649Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.Cancer Treat Rev2004https://conductscience.org/library/papers/15059649PubMed
141400622A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections.J Cell Biochem1992https://conductscience.org/library/papers/1400622PubMed
1518158788Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.Hybridoma (Larchmt)2007https://conductscience.org/library/papers/18158788PubMed
169154469Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.Immunotechnology1997https://conductscience.org/library/papers/9154469PubMed
171728407A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.Cancer Res1992https://conductscience.org/library/papers/1728407PubMed

Download CSV of references

Cited by115

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 198 citations.

PMIDTitleJournalYearIn PapersSource
41929496Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient.Front Immunol2026https://conductscience.org/library/papers/41929496PubMed
41916997
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial.
Nat Commun2026https://conductscience.org/library/papers/41916997PubMed
41618610Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy.J Extracell Vesicles2026https://conductscience.org/library/papers/41618610PubMed
41318392Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma.BMC Cancer2025https://conductscience.org/library/papers/41318392PubMed
40881676Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Front Immunol2025https://conductscience.org/library/papers/40881676PubMed
40859900EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40859900PubMed
40672372Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma.Front Pharmacol2025https://conductscience.org/library/papers/40672372PubMed
40335598Prognostic analysis of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer: a multicenter real-world study.Sci Rep2025https://conductscience.org/library/papers/40335598PubMed
39838362Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis.BMC Cancer2025https://conductscience.org/library/papers/39838362PubMed
39767654Coley's Toxin to First Approved Therapeutic Vaccine-A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.Biomedicines2024https://conductscience.org/library/papers/39767654PubMed
39339232Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer.Pharmaceutics2024https://conductscience.org/library/papers/39339232PubMed
38939342Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials.Front Oncol2024https://conductscience.org/library/papers/38939342PubMed
38806289Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.Cancer Sci2024https://conductscience.org/library/papers/38806289PubMed
38675134Evaluation of Advanced Nanomaterials for Cancer Diagnosis and Treatment.Pharmaceutics2024https://conductscience.org/library/papers/38675134PubMed
38549541Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.Curr Cancer Drug Targets2024https://conductscience.org/library/papers/38549541PubMed
38473402Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.Cancers (Basel)2024https://conductscience.org/library/papers/38473402PubMed
38090376Busting the Breast Cancer with AstraZeneca's Gefitinib.Adv Pharmacol Pharm Sci2023https://conductscience.org/library/papers/38090376PubMed
37864049Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.Br J Cancer2023https://conductscience.org/library/papers/37864049PubMed
37724258Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.Med Rev (2021)2022https://conductscience.org/library/papers/37724258PubMed
37458862Oncolytic viruses against cancer, promising or delusion?Med Oncol2023https://conductscience.org/library/papers/37458862PubMed

See all 115 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20046573

GET https://conductscience.org/api/papers/v1/20046573/cited_by?page=2